Hong Kong S.a.r.
Innorna, founded in 2019 and headquartered in Hong Kong S.a.r., is a promising player in the Biotechnology and Pharmaceutical sectors. The company is dedicated to "Advancing RNA Medicines by Accelerating a Virtuous Cycle of Platform and Pipeline Innovation."
This clinical-stage biotech has developed a proprietary RNA delivery and engineering platform, consisting of over 6,000 chemically diverse ionizable lipids, targeted LNP delivery systems, and mRNA technologies. These innovations drive a comprehensive, vertically integrated approach from discovery through cGMP manufacturing, enhancing both technical expertise and capital efficiency.
Innorna has successfully raised $150 million, including a substantial $120 million Series B in March 2022 from investors like CDH Investments, Fangyuan Rongtong Group, CPE, and Huaxing Healthcare Fund. With robust financing and a focus on strategic growth partnerships, Innorna is positioned well for achieving key clinical milestones and expanding its mRNA pipeline in chronic diseases, immunotherapies, and vaccines.
